Hyponatremia in Patients with Hematologic Diseases. [PDF]
J Clin Med, 2020 Hyponatremia is the most common electrolyte disorder in clinical practice and is associated with increased morbidity and mortality. It is frequently encountered in hematologic patients with either benign or malignant diseases. Several underlying mechanisms, such as hypovolemia, infections, toxins, renal, endocrine, cardiac, and liver disorders, as well
Koumpis E +3 more
europepmc +6 more sources
COVID-19 in Patients with Hematologic Diseases. [PDF]
Biomedicines, 2022 The COVID-19 outbreak had a strong impact on people’s lives all over the world. Patients with hematologic diseases have been heavily affected by the pandemic, because their immune system may be compromised due to anti-cancer or immunosuppressive ...
Casetti IC, Borsani O, Rumi E.
europepmc +2 more sources
Bloodstream Infections in Patients with Hematologic Diseases: Causative Organisms and Factors Associated with Resistance. [PDF]
Infect Chemother, 2022 Background Patients with hematologic diseases are at high risk of bloodstream infections (BSIs). This study aimed to analyze clinical features and distributions of microorganisms in patients with hematologic diseases presenting at a tertiary care ...
Choi H, Ahn H, Lee R, Cho SY, Lee DG.
europepmc +2 more sources
Advances in prophylaxis and treatment of invasive fungal infections: perspectives on hematologic diseases. [PDF]
Blood Res, 2022 Invasive fungal infections (IFIs) are common causes of mortality and morbidity in patients with hematologic diseases. Delayed initiation of antifungal treatment is related to mortality. Aspergillus sp.
Ahn H, Lee R, Cho SY, Lee DG.
europepmc +2 more sources
Invasive Fusariosis in Patients with Hematologic Diseases. [PDF]
J Fungi (Basel), 2021 Fusarium species are filamentous fungi widely encountered in nature, and may cause invasive disease in patients with hematologic conditions. Patients at higher risk are those with acute leukemia receiving induction remission chemotherapy or allogeneic ...
Nucci M +4 more
europepmc +2 more sources
Immune Response after 2 Doses of BNT162b2 mRNA COVID-19 Vaccinations in Children and Adolescents with Cancer and Hematologic Diseases. [PDF]
Asian Pac J Cancer Prev, 2022 Background: The BNT162b2 mRNA COVID-19 vaccine has been administered to children and adolescents with cancer and hematologic diseases since they are at high risk of manifesting severe symptoms if they have COVID-19 infection but the adequate immune ...
Poparn H +7 more
europepmc +2 more sources
KSHV/HHV8-mediated hematologic diseases.
Blood, 2022 The Kaposi sarcoma herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is the causal agent of Kaposi sarcoma (KS), but is also pathogenetically related to several lymphoproliferative disorders, including primary effusion lymphoma (PEL)/extra ...
Cesarman E, Chadburn A, Rubinstein PG.
europepmc +2 more sources
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases [PDF]
Blood, 1998 Myeloablative conditioning associated with hazardous immediate and late complications is considered as a mandatory first step in preparation for allogeneic blood or marrow transplantation (allogeneic BMT) for the treatment of malignant hematologic ...
Shimon Slavin +14 more
openalex +2 more sources
Movement Disorders and Hematologic Diseases. [PDF]
Mov Disord Clin Pract, 2021 AbstractBackgroundMovement disorders can be associated with or caused by hematological abnormalities. The objective of this review is to highlight features that will aid in the clinician's recognition and treatment of these disorders.MethodsMESH terms relevant to movement disorders and hematologic diseases were searched to identify conditions included ...
Patel RA +3 more
europepmc +5 more sources
Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases. [PDF]
Hematology Am Soc Hematol Educ Program, 2020 Corticosteroids constitute a first-line therapy for adults and children suffering from nonmalignant immune-mediated hematologic diseases. However, high disease relapse rates during the tapering period or upon drug discontinuation result in long-term ...
Malpica L, Moll S.
europepmc +2 more sources